Likar Conclusions Buprenorphine has been widely used and studied for over 20 years and shown to be an effective opioid analgesic. The µ-agonistic profile of buprenorphine, combined with high analgesic potency and efficacy, good safety profile, ease of opioid switch, and reversibility by µ-antagonists makes this drug a valuable option for long-term treatment in a wide range of chronic pain indications. By using the transdermal formulation of buprenorphine, the rate of drug delivery can be controlled and stable plasma concentrations achieved. The transdermal administration route is an advantage for long-term use in ease of handling, increased patient compliance, and cost-effectiveness of treatment. References Atkinson RE, Schofield P, Mellor P. 1990. The efficacy in sequential use of buprenorphine and morphine in advanced cancer pain. In: Doyle D (ed). Opioids in the treatment of cancer pain. The Royal Society of Medicine Services International Congress and Symposium Series, London. No 146. Bach V, Kamp-Jensen M, Jensen N-H, et al. 1991. Buprenorphine and sustained release morphine – effect and side-effects in chronic use. The Pain Clinic, 4:87–93. Benedetti F, Vighetti S, Amanzio M, et al. 1998. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain, 74:205–11. Berner B, John VA. 1994. Pharmacokinetic characterization of transdermal delivery systems. Clin Pharmacokinet, 26:121–34. Bickel WK, Stitzer ML, Bigelow GE, et al. 1988. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther, 43:72–8. Boas RA, Villiger JW. 1985. Clinical actions of fentanyl and buprenorphine: the significance of receptor binding. Br J Anaesth, 57:192–6. Böhme K, Likar R. 2003. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomized, double- blind, placebo-controlled study. The Pain Clinic, 15:193–202. Budd K.1981. High dose buprenorphine for postoperative analgesia. Anaesthesia, 36:900–3. Budd K. 2002. Buprenorphine: a review. In: Evidence based medicine in practice. Newmarket, UK: Hayward Medical Communications. p 1–24. Budd K. 2003. Old dog –new (ma)trix. Br J Anaesth, 90:2–4. Budd K. 2004. Acute pain, the immune system and opioidimmuno- suppression. Acute Pain, 6:123–35. Bullingham RES, McQuay HJ, Moore A, et al. 1980. Buprenorphine kinetics. Clin Pharmacol Ther, 28:667–72. Dahan A, Yassen A, Bijl H, et al. 2005. A comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans rats. Br J Anaesth, 94:825–34. Davies G, Kingswood C, Street M. 1996. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet, 31:410–22. Dertwinkel R, Donner B, Zenz M, et al. 1998. Opioids in chronic pain. Bailliere Clin Anaesth, 12:39–52. Donner B, Zenz M, Tryba M, et al. 1996. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain, 64:527–34. Doxey JC, Everitt JE, Frank LW, et al. 1982. A comparison of the effects of buprenorphine and morphine on the blood gases of conscious rats. Brit J Pharmacol, 75:118P. 124 Filitz J, Griessinger N, Sittl R, et al. 2006. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain, in press. Gal TJ. 1989. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther, 45:66–71. Griessinger N, Sittl R, Likar R. 2005. Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin, 21:1147–56. Hand CW, Sear JW, Uppington J, et al. 1990. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth, 64:276–82. Harcus AW, Ward AE, Smith DW. 1979. Methodology of monitored release of a new preparation: buprenorphine. Br Med J, 2:163–5. Heel RC, Brogden RN, Speight TM, et al. 1979. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs, 17:81–110. Ibrahim R, Wilson JG, Thorsby ME, et al. 2000. Excessive CNS depression due to the combination of buprenorphine and benzodiazepines is most likely due to additive or synergistic pharmacologic effects unrelated to a pharmacokinetic interaction between the drugs. Life Sci, 66: 1293–8. Jasinski DR, Pevnick JS, Griffith JD. 1978. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry, 35:501–16. Kamal RS, Khan FA. 1995. Caudal analgesia with buprenorphine for postoperative pain relief in children. Paedriatr Anaesth, 5:101–6. Kay B. 1978. A double-blind comparison of morphine and buprenorphine in the prevention of pain after operation. Br J Anaesth, 50:605–9. Koegel B, Christoph T, Strassburger W, et al. 2005. Interaction of µ-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain, 9:599–611. Koppert W, Ihmsen H, Körber N, et al. 2005. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain, 118:15–22. Leander JD, 1988. Buprenorphine is a potent k-opioid receptor antagonist in pigeons and mice. Eur J Pharmacol, 151:457–61. Lewis JW, 1985. Buprenorphine. Drug Alcohol Depend, 14:363–72. Likar R, Griessinger N, Sadjak A, et al. 2003. Transdermal buprenorphine for the treatment of chronic cancer and noncancer pain (article in German). Wien Med Woschr, 153:317–22. Likar R, Kayser H, Sittl R. 2005. Transdermal buprenorphine for long- term management of chronic cancer and non-cancer pain. Results of an open-label, multicentre, follow-up study. Book of Abstracts, International Forum on Pain Medicine. May 5–8, Sofia, Bulgaria. Likar R. 2005. Efficacy and safety of a buprenorphine-transdermal patch with 4 days’ wearing time compared with the current application period of 3 days – a randomized cross-over study. Book of Abstracts, 4th International Conference on Pain Control and Regional Anaesthesia, 18–22 November, Cape Town, South Africa. Likar R, Sittl R. 2005. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg, 100:781–85. Lutfy K, Eitan S, Bryant CD, et al. 2003. Buprenorphine-induced antinociception is mediated by µ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci, 23:10331–7. Ly LP, Jimenez M, Zhuang TN, et al. 2001. A double-blind, placebo- controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab, 86: 4078–88. Martin WR, Eades CG, Thompson JA, et al. 1976. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine- dependent chronic spinal dog. J Pharmacol Exp Ther, 197:517–32. Martucci C, Panerai AE, Sacerdote P. 2004. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain, 110:385–92. Therapeutics and Clinical Risk Management 2006:2(1)